A simple and low-energy method to prepare loratadine nanosuspensions for oral bioavailability improvement: preparation, characterization, and in vivo evaluation

被引:0
作者
Dandan Yang
Ruirui Li
Fang Zhang
Li Qin
Feifei Peng
Shanshan Jiang
Huiyang He
Xiumei Lu
Peng Zhang
机构
[1] Shenyang Pharmaceutical University,School of Pharmacy
来源
Drug Delivery and Translational Research | 2020年 / 10卷
关键词
Loratadine; Nanosuspensions; Effervescent method; Bioavailability;
D O I
暂无
中图分类号
学科分类号
摘要
The effervescent method, as a simple and effective technology to prepare nanosuspensions, has gained great attention. In this present research, loratadine (LTD) nanosuspensions were successfully prepared by the effervescent method using Soluplus as stabilizer to improve the bioavailability of LTD in vivo. The mean particle size was about 100 nm. And the LTD nanosuspensions were lyophilized for further study. The freeze-dried powders could be dissolved quickly, and the mean particle size remained almost unchanged after powders were re-dissolved. By transmission electron microscope (TEM), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy, and X-ray diffraction (X-RD), the characterizations of LTD nanosuspensions and freeze-dried powders were studied. Commercial tablets were used as the reference to investigate the dissolution behaviors in different release media and of bioavailability in vivo of LTD freeze-dried powders. The cumulative dissolution of the LTD freeze-dried powders was superior in different release media compared with commercial tables. In addition, for the evaluation of the bioavailability of LTD nanosuspensions, the LTD concentration in rat plasma was determined using LC-MS/MS method. The results showed that the AUC0–24 and Cmax of LTD freeze-dried powders were about 2.14- and 2.01-fold higher than those of commercial tablets. In short, the effervescent method has been successfully applied to the preparation of LTD nanosuspensions to improve the bioavailability of LTD in vivo with the advantage of low energy consumption. This simple technology also provides an idea for the preparation of the other nanosuspensions.
引用
收藏
页码:192 / 201
页数:9
相关论文
共 105 条
[1]  
Stegemann S(2007)When poor solubility becomes an issue: from early stage to proof of concept Eur J Pharm Sci 31 249-261
[2]  
Leveiller F(2008)Passive oral drug absorption can be predicted more reliably by experimental than computational models-fact or myth Eur J Pharm Sci 34 129-139
[3]  
Franchi D(2014)Biocompatible riboflavin laurate long-acting injectable nanosuspensions allowing sterile filtration Drug Deliv 21 351-361
[4]  
de Jong H(2011)Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology Adv Drug Deliv Rev 63 427-440
[5]  
Linden H(2012)Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release AAPS PharmSciTech 13 53-58
[6]  
Linnankoski V-PR(2017)Loratadine bioavailability via buccal transferosomal gel: formulation,statistical optimization, in vitro/in vivo characterization, and pharmacokinetics in human volunteers Drug Deliv 24 781-791
[7]  
Yliperttula M(2011)Physicochemical characterization and in vitro/in vivo evaluation of loratadine: dimethyl-β-cyclodextrin inclusion complexes J Pharm Biomed Anal 55 294-300
[8]  
Urtti A(2015)Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine J Microencapsul 32 175-180
[9]  
Hu X(2009)Acid-base equilibria and solubility of loratadine and desloratadine in water and micellar media J Pharm Biomed Anal 49 42-47
[10]  
Lin X(2013)Dissolution rat enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods Powder Technol 235 532-539